FDA Approved the First Tissue-Agnostic Molecularly Targeted Therapeutic for Cancer
The FDA approved the first molecularly targeted therapeutic for use based on a tumor biomarker rather than where the cancer originates.
Progress Against Cancer
The FDA approved the first molecularly targeted therapeutic for use based on a tumor biomarker rather than where the cancer originates.
The FDA approved two separate molecularly targeted therapeutics for treating patients aged 75 or older with acute myeloid leukemia (AML).
The FDA expanded the use of the immunotherapy pembrolizumab to include the treatment of certain patients with liver cancer.
The FDA approved a molecularly targeted therapeutic for treating certain patients with metastatic non-small cell lung cancer.
The FDA approved a targeted therapeutic for treating patients with breast cancer that tests positive for a cancer-associated BRCA1 or BRCA2 mutations.
The FDA approved a molecularly targeted therapeutic for treating certain patients with non-small cell lung cancer.
The FDA approved a new molecularly targeted therapeutic called for treating certain patients with blood cancer.
The FDA approved a new immunotherapeutic for treating patients with a type of skin cancer called cutaneous squamous cell carcinoma.
The FDA expanded the use of nivolumab to include treating certain patients with small cell lung cancer.
The FDA approved a new molecularly targeted therapeutic for treating certain patients with a rare form of leukemia called hairy cell leukemia.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More